Casey G. Langdon

436 total citations
13 papers, 298 citations indexed

About

Casey G. Langdon is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Casey G. Langdon has authored 13 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Casey G. Langdon's work include Melanoma and MAPK Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Casey G. Langdon is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). Casey G. Langdon collaborates with scholars based in United States, Switzerland and Italy. Casey G. Langdon's co-authors include David F. Stern, Marcus Bosenberg, James T. Platt, Matthew A. Held, Andrew B. Koo, Zongzhi Liu, Jonathan W. Haskins, Antonella Bacchiocchi, Ashok K. Chakraborty and Nicholas Theodosakis and has published in prestigious journals such as Nature Communications, Cancer Research and Journal of Investigative Dermatology.

In The Last Decade

Casey G. Langdon

13 papers receiving 294 citations

Peers

Casey G. Langdon

ONCOL

CTM

PRM

Elizabeth A. Coker United Kingdom

Neus Cantariño Spain

Yasushi Tomii Japan

Thuerigen Olaf Germany

Valeria Sanabria Guillen United States

Grazia Saturno Italy

Huikun Zhang China

James Zweibel United States

Deborah Moshinsky United States

Hélène Malka-Mahieu France

Elizabeth A. Coker United Kingdom

Casey G. Langdon

286 ×1.2

101 ×0.9

ONCOL

108 ×1.7

CTM

76 ×1.3

38 ×1.1

PRM

Citations per year, relative to Casey G. Langdon Casey G. Langdon (= 1×) peers Elizabeth A. Coker

Countries citing papers authored by Casey G. Langdon

Since Specialization

Citations

This map shows the geographic impact of Casey G. Langdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Casey G. Langdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Casey G. Langdon more than expected).

Fields of papers citing papers by Casey G. Langdon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Casey G. Langdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Casey G. Langdon. The network helps show where Casey G. Langdon may publish in the future.

Co-authorship network of co-authors of Casey G. Langdon

This figure shows the co-authorship network connecting the top 25 collaborators of Casey G. Langdon. A scholar is included among the top collaborators of Casey G. Langdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Casey G. Langdon. Casey G. Langdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Langdon, Casey G.. (2023). Nuclear PTEN’s Functions in Suppressing Tumorigenesis: Implications for Rare Cancers. Biomolecules. 13(2). 259–259. 14 indexed citations

Hanna, Jason A., Casey G. Langdon, Matthew R. Garcia, et al.. (2022). Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2‐Cre mice. The Journal of Pathology. 257(1). 109–124. 6 indexed citations

Langdon, Casey G., Matthew R. Garcia, Myron K. Evans, et al.. (2021). Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity. Nature Communications. 12(1). 5520–5520. 14 indexed citations

Langdon, Casey G. & Mark E. Hatley. (2021). The perfect PTEN – transcriptional regulation by PTEN dictates sarcoma identity. Molecular & Cellular Oncology. 8(6). 2002120–2002120. 1 indexed citations

Theodosakis, Nicholas, Casey G. Langdon, Goran Micevic, et al.. (2018). Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer. Pigment Cell & Melanoma Research. 32(2). 292–302. 18 indexed citations

Langdon, Casey G., James T. Platt, Robert E. Means, et al.. (2017). Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Molecular Cancer Therapeutics. 16(6). 1041–1053. 12 indexed citations

Theodosakis, Nicholas, Goran Micevic, Casey G. Langdon, et al.. (2017). p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. Journal of Investigative Dermatology. 137(10). 2187–2196. 25 indexed citations

Wali, Vikram B., Casey G. Langdon, Matthew A. Held, et al.. (2016). Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Research. 77(2). 566–578. 38 indexed citations

Scortegagna, Marzia, Eric Lau, Tongwu Zhang, et al.. (2015). PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Research. 75(7). 1399–1412. 44 indexed citations

10.

Langdon, Casey G., Matthew A. Held, James T. Platt, et al.. (2015). The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF ‐mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell & Melanoma Research. 28(4). 417–430. 13 indexed citations

11.

Langdon, Casey G., Norbert Wiedemann, Matthew A. Held, et al.. (2015). Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma. Cancer Research. 75(15_Supplement). 2529–2529. 1 indexed citations

12.

Langdon, Casey G., Norbert Wiedemann, Matthew A. Held, et al.. (2015). SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget. 6(35). 37410–37425. 16 indexed citations

13.

Held, Matthew A., Casey G. Langdon, James T. Platt, et al.. (2012). Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery. 3(1). 52–67. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact